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In this study, an episomal system for ecdysone-inducible gene expression was developed. Human embryonic kidney 293
cells (293VE) expressing a heterodimer of modified ecdysone and retinoid X receptors and the Epstein–Barr nuclear
antigen-1 were screened. Plasmids containing the EBV replication origin, oriP, and the ecdysone-response element could
replicate and persist in 293VE cells to inducibly express luciferase or Vpr. The induction level, tested with luciferase reporter
plasmid, varied among cell lines from 254- to 2056-fold. In one highly inducible cell line, HIV-1 Vpr was expressed well and
caused G2 cell cycle arrest in the presence of the inducer, while in the absence of the inducer, no Vpr protein or cell cycle
arrest could be detected. Using different selection markers, HIV-1 Vpr was coexpressed with Vpr mutants defective in
phosphorylation at Ser79 and G2 cell cycle arrest activity. These Vpr mutants were transdominant to wild-type Vpr for G2 cell
cycle arrest activity, but did not alter wild-type Vpr phosphorylation. It is likely that the transdominant mutants and wild-type
Vpr compete for a downstream target(s) of G2 cell cycle arrest. © 2001 Academic Press
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Human immunodeficiency virus type 1 (HIV-1), the eti-
ologic agent of AIDS, is a member of the lentivirus family.
In addition to the common retroviral structural proteins,
Gag, Pol, and Env, HIV-1 encodes two regulatory pro-
teins, Tat and Rev, and at least four auxiliary proteins, Vif,
Vpr, Vpu, and Nef, that may be dispensable for in vitro
replication, but are necessary for HIV pathogenesis
(Cullen and Green, 1990; Subbramanian and Cohen,
1994). Vpr is a 14-kDa nuclear protein present at high
copy number in HIV-1 virions (Cohen et al., 1990; Wong-
Staal et al., 1987). Several studies have shown that HIV-1
Vpr is involved in the nuclear import of the HIV-1 prein-
tegration complex (Heinzinger et al., 1994; Lu et al., 1993;
Mahalingam et al., 1997, 1998; Yao et al., 1995). Also, Vpr
induces G2 cell cycle arrest in proliferating human cells
(Agostini et al., 1996, 1999; Felzien et al., 1998; Goh et al.,
1998; Hrimech et al., 1999; Kino et al., 1999; Wang et al.,
1995), has ion channel activity (Piller et al., 1996), inter-
feres with the rate of DNA mutation (Jowett et al., 1999;
Mansky, 1996), and induces micronuclei formation
(Minemoto et al., 1999).
One of the important functions of Vpr is to promote cell
cycle arrest at the G2 phase. Both de novo and virion-
packaged Vpr can induce cell cycle arrest, but the role of
1 To whom correspondence and reprint requests should be ad-
ressed at Washington University School of Medicine, Box 8069, 660 S.
uclid Avenue, St. Louis, MO 63110. Fax: (314) 747-2797. E-mail:
ratner@imgate.wustl.edu.133Vpr-induced G2 cell cycle arrest in HIV-1 pathogenesis is
as yet unclear. It has been suggested that the G2 cellular
environment is more suitable for high level of HIV repli-
cation and immune evasion, thus facilitating the persis-
tence of the virus within the infected individual (Goh et
al., 1998; Stewart et al., 1997). Vpr prevents cell prolifer-
ation and mitosis in human and primate cells as well as
in yeast, suggesting that Vpr targets a general cellular
pathway (Macreadie et al., 1995; Planelles et al., 1996). In
Vpr-expressing cells, the p34(cdc2)–cyclin B complex is
inactivated by hyperphosphorylation of p34(cdc2) (He et
al., 1995; Jowett et al., 1995). Cellular proteins, such as
HHR23A and hmov34, have been shown to interact with
HIV-1 Vpr but none of them has been identified as the
factor required for Vpr G2 cell cycle arrest (Gragerov et
al., 1998; Mahalingam et al., 1998; Withers-Ward et al.,
1997). In addition, the relation between the expression of
Vpr and the fate of the cells is still unclear since both
proapoptotic and antiapoptotic activities of Vpr have
been reported (Ayyavoo et al., 1997; Conti et al., 1998;
Fukumori et al., 1998; Glynn et al., 1996; He et al., 1995;
Jowett et al., 1995; Stewart et al., 1997). Recently, our
results have suggested that phosphorylation of Vpr at
Ser79 is critical for Vpr G2 cell cycle arrest and may be
involved in the regulation of Vpr G2 cell cycle arrest
(Zhou and Ratner, 2000). However, the exact mechanism
of Vpr G2 cell cycle arrest and its regulation through
phosphorylation are still unclear.
Since HIV-1 Vpr arrests cells in the G2 phase of the
cell cycle and inhibits cell growth, it is difficult to gener-
ate stable Vpr-expressing cell lines in order to analyze its0042-6822/01 $35.00
Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
T
w
s
e
p
a
i
c
T
l
w
s
a
a
c
P
t
134 ZHOU AND RATNERbiological function. Although a few cell lines have been
characterized, they did not exhibit G2 cell cycle arrest
activity (Conti et al., 1998; Fukumori et al., 1998). This
implies that long-term expression of Vpr may alter its
effects on the cell cycle or that these cell lines may
possess mutated Vpr. Therefore these cell lines are not
suitable for studies of the Vpr G2 cell cycle arrest. Re-
cently, HIV-1 Vpr was expressed using a tetracycline-
inducible system to study its biological functions
(Shimura et al., 1999).
In this study, we describe a new system for the induc-
ible expression of different Vpr mutants in the same
cellular background to study HIV-1 Vpr functions. It is
derived from the combination of the ecdysone-inducible
gene expression system and episomal vector system.
Since the tetracycline-inducible system is not suitable for
some cell types, due to high background expression, we
chose the ecdysone-inducible system to tightly regulate
Vpr expression in human embryonic kidney (HEK) 293
cells (Howe et al., 1995; No et al., 1996). The ecdysone-
inducible eukaryotic gene expression system was devel-
oped by No et al. and has been used to regulate gene
expression in vitro and in vivo (No et al., 1996). Briefly,
stable cell lines expressing a heterodimer of the modi-
fied ecdysone receptor (VgEcR) and the retinoid X recep-
tor (RXR) are clonally selected. The heterodimer binds a
hybrid ecdysone response element (E/GRE) only in the
presence of the synthetic analog of ecdysone. The highly
inducible cell lines are then transfected with plasmid
pIND containing the gene of interest, followed by clonal
selection, and functional testing of individual clones for
regulated gene expression (No et al., 1996). The episo-
mal vector is derived from Epstein–Barr virus (EBV) rep-
lication and needs the EBV nuclear antigen 1 (EBNA1) to
support EBV replication origin, oriP, replication. To com-
bine the ecdysone-inducible gene expression and the
episomal vector systems, 293 cells expressing RXR/
VgEcR and EBNA1 were screened to support the episo-
mal vector containing the E/GRE and EBV oriP for repli-
cation and ecdysone-inducible gene expression. Our re-
sults indicate that the new episomal vector was
maintained in 293VE cells and the cloned gene was
tightly regulated by the inducer. Using different selection
markers, wild-type Vpr and Vpr mutants defective in G2
cell cycle arrest activity were inducibly coexpressed.
These Vpr mutants were transdominant to wild-type Vpr
in G2 cell cycle arrest activity. Further analysis suggests
that transdominant mutants did not alter wild-type Vpr
phosphorylation. It is likely that transdominant mutants
and wild-type Vpr compete for a downstream target(s).
RESULTS
Screening pVgRXR/EBNA1 cells
HEK293 cells were cotransfected with pVgRXR and
pCMV-EBNA1, and the Zeocin-resistant colonies were lpicked. The individual clonal cell lines were amplified
and transfected with plasmid pIND-LacZ. The trans-
fected cells were split into duplicate wells and cultured
in the absence or presence of 1 mM muristerone A.
wenty-four hours after induction, the cells were stained
ith X-gal. The cell lines without blue color in the ab-
ence of inducer and with strong blue color in the pres-
nce of inducer were further analyzed (data not shown).
The selected cell lines were then transfected with
ZY-Luc and then split and cultured in the presence or
bsence of the inducer, 1 mM muristerone A. The gene
nduction levels and background expression of these cell
olonies were determined by luciferase assay (Fig. 1A).
he induction levels ranged from 254- to 2056-fold. Cell
ine 632 exhibited the highest level of induction. To test
hether these cell lines were inducible for Vpr expres-
ion, pZY-Vpr was transfected into each 293VE cell line
nd selected with G418 as described under Materials
nd Methods. The Vpr expression from each resistant
ell line was analyzed by immunoprecipitation, SDS–
AGE, and phosphoimaging (Fig. 1B). It is interesting that
he Vpr gene expression did not correlate well with
FIG. 1. Characterization of 293 (pVgRxR/EBNA1) cell lines for protein
induction. (A) 293VE cell lines were transfected with pZY-Luc and
cultured for 48 h. The cells were split and incubated with or without 1
mM muristerone A for another 24 h and luciferase assays were per-
formed. The fold induction was calculated by dividing luciferase counts
in the presence of inducer by those obtained in the absence of inducer.
(B) pZY-Vpr-transfected cells were selected in the presence of 750
mg/ml G418 for 5 days and were labeled with 100 mCi/ml Tran[35S]label
for 16 h in the presence or absence of the inducer. The labeled Vpr was
immunoprecipitated from cell lysates with anti-Vpr serum, normalized
for total 35S counts, and separated by SDS–PAGE, and the dried gel was
exposed on a Bio-Rad phosphoimager. The relative counts represent
the counts in the selected box area containing the Vpr band while
subtracting the background counts. The background counts for each
lane are the average counts from the same box area above and under
the Vpr band.uciferase activity. For example, cell lines 28, 31, and 41
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135A NOVEL INDUCIBLE SYSTEM FOR HIV-1 Vprhad high luciferase expression but not HIV-1 Vpr expres-
sion. Cell lines 7, 19, and 42 had only moderate levels of
Vpr expression. In contrast, cell lines 10, 39, and 632
expressed Vpr well, with cell line 632 exhibiting the best
Vpr induction level (Fig. 1B).
The resistant cells were also tested for Vpr-induced
G2 cell cycle arrest by PI staining. Cell lines 39 and 632
exhibited significant G2 cell cycle arrest activity with
muristerone A induction. The other cell lines exhibited
little or no G2 cell cycle arrest (data not shown). It is
worth noting that the G2 cell cycle arrest activity corre-
sponded well to Vpr gene expression, suggesting that a
threshold level of HIV-1 Vpr expression is required for G2
cell cycle arrest in 293VE cells.
Ecdysone-regulated expression of Vpr in 293VE-632
cells
To compare the ecdysone-dependent regulation of the
gene expression from the episomal construct (pZY-1) to
that of original ecdysone-regulatable construct pIND-Vpr
lacking oriP, pIND-Vpr was transfected into 293VE-632
ells. The transiently pIND-Vpr-transfected cells and the
418-resistant cells from pZY-1 or pZY-Vpr transfection
ere metabolically labeled with Tran[35S]label. 35S-la-
beled Vpr was detected by immunoprecipitation with
anti-Vpr antibodies and SDS–PAGE. The results indicated
that both pIND-Vpr and pZY-Vpr can inducibly express
Vpr in the presence of 1 mM muristerone A, and no
background expression of Vpr was detected in the ab-
sence of the inducer (Fig. 2A).
To examine the effects of Vpr on the cell cycle, resis-
tant pZY-1- or pZY-Vpr-transfected cells were stained with
PI as described under Materials and Methods. In the
presence of the inducer, 293VE-632 (pZY-Vpr) cells ar-
rested in the G2 phase after induction of Vpr for 36 h. In
the absence of the inducer, no G2 cell cycle arrest was
observed. The control transfected 293VE-632 (pZY-1)
cells were not arrested in the presence or absence of the
inducer (Fig. 2B). Due to the overgrowth of untransfected
cells after pIND-Vpr transfection, G2 cell cycle arrest was
not detected 2 days after induction in the presence of the
inducer (data not shown).
Ecdysone-regulated stable Vpr expression cell lines
Because a chromosomal recombinant cell line may
express the integrated gene homogeneously, we tested
whether 293VE-632 cells were suitable for generating
ecdysone-regulated chromosomal recombinant stable
cell lines for HIV-1 Vpr expression. pIND-Vpr and pIND-
LacZ were transfected separately into 293VE-632 cells
and screened as described under Materials and Meth-
ods. Individual colonies were expanded and analyzed for
gene expression and biological function. All 20 colonies
from pIND-LacZ transfection expressed b-galatosidase,
but the expression levels varied (data not shown). Toanalyze Vpr function, the individual colonies from pIND-
Vpr transfection were stained with PI in the presence or
absence of the inducer. Twenty of 167 cell lines showed
no effect on the cell cycle in the presence or absence of
the inducer (data not shown). The remaining colonies
exhibited cell cycle arrest, but the level of arrest varied
among the cell lines (data not shown). We randomly
chose 1 cell line not exhibiting G2 arrest (1–6) (Fig. 3,
lane 1) and 4 cell lines exhibiting G2 arrest (1–18, 1–53,
2–4, and 2–34) (Fig. 3, lanes 2–5) to assess HIV-1 Vpr
expression by immunoprecipitation. No Vpr expression
could be detected from the 1–6 cell line, while Vpr ex-
pression was clearly detected from the 1–18, 1–53, 2–4,
and 2–34 cell lines in the presence of the inducer. No cell
cycle effect or Vpr expression could be detected in the
absence of inducer from any of these cell lines (data not
FIG. 2. Vpr expression and G2 cell cycle arrest. (A) The 293VE-632
cell line was transfected with pIND-Vpr, pZY-1, or pZY-Vpr and selected
with 750 mg/ml G418 for 5 days. The resistant cells were split and
labeled with Tran[35S]label for 16 h in the absence or presence of the
nducer. The labeled Vpr was immunoprecipitated with anti-Vpr anti-
erum. Duplicate experiments are shown for pIND-Vpr- and pZY-Vpr-
ransfected cells. Lane M includes molecular weight markers with a
4.3-kDa protein indicated as the smallest marker band. (B) The resis-
ant cells were split and cultured for an additional 36 h in the presence
r absence of 1 mM muristerone A. Cell cycle arrest activity was
nalyzed by propidium iodide staining followed by FACScan analysis.
he G1 and G2/M peaks are indicated and the proportion of cells in
ach peak is shown in the upper right corner.shown).
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136 ZHOU AND RATNERCoexpression of Vpr and transdominant Vpr mutants
To test whether this system could be used to regulate
the expression of two proteins simultaneously to study
protein–protein interactions, Vpr and Vpr G2 cell cycle
null mutants (mVpr) 79A, 79D, or 79Q (Fig. 4A and Zhou
and Ratner, 2000) were coexpressed by transfection of
either pZY-Vpr/pZH-mVpr or pZH-Vpr/pZY-mVpr into
293VE-632 cells at a 1:1 ratio (Figs. 4A and 4B). The
cotransfected cells were selected with a combination of
antibiotics (Zeocin, G418, and hygromycin) for 7 days and
the resistant cells were then tested for G2 cell cycle
arrest (Fig. 4B). When pZY-Vpr was cotransfected with
control vector pZH-1, the cells were arrested in the G2
phase, suggesting that additional plasmid did not affect
Vpr expression (Fig. 4B, top left). Compared to pZH-1
control, coexpression of wild-type Vpr with G2 cell cycle
arrest null Vpr mutants pZH-Vpr79A, -Vpr79D, or -Vpr79Q
resulted in a decrease of the G2 cell cycle arrest (Fig. 4B,
top right three). Similar results were observed when
wild-type Vpr was expressed from pZH-1 vector and
mutant Vpr was expressed from pZY-1 vector (Fig. 4B,
bottom). It is possible that two plasmids compete for
replication and/or result in decrease of wild-type Vpr
expression. Therefore, we transfected pZH-1, pZH-79A,
pZH-79D, and pZH-79Q into the stable cell lines 1–18 and
1–53. These resistant cells were analyzed for G2 cell
cycle arrest. The three Vpr mutants almost completely
blocked the Vpr G2 cell cycle arrest activity, while control
plasmid pZH-1 had no effect (data not shown). Therefore,
it is unlikely that mutant Vpr affected the wild-type Vpr
gene expression, but it is more likely that the mutant Vpr
was transdominant to the wild-type Vpr G2 cell cycle
arrest activity.
In order to distinguish wild-type Vpr from mutant Vpr
FIG. 3. Determination of Vpr expression and G2 cell cycle effect in
the 293VE-Vpr stable cell lines. Each stable cell line was plated at 1.0 3
106 cells/well in a six-well plate and cultured for 24 h. The cells were
labeled with Tran[35S]label in the presence of the inducer overnight. Vpr
proteins were detected by immunoprecipitation with anti-Vpr serum.
The cell cycle analysis was carried out as described under Materials
and Methods. The G1/(G2/M) ratios in the presence of the inducer (1)
as well as the ratios for experiments performed in the absence of
inducer (2) versus the presence of inducer (1) are listed.and to quantitate the levels of each protein, a HA-tagged pVpr coding sequence was cloned into pZH-1 (pZH-HA-
Vpr). HA-Vpr was shown to arrest cells as well as wild-
type Vpr (Di Marzio et al., 1995). pZH-HA-Vpr was co-
transfected with the pZY-mVpr constructs at different
ratios, 1:1, 4:1, or 1:4, as shown in Fig. 4C. The resistant
cells were labeled with Tran[35S]label and immunopre-
ipitated with anti-Vpr antiserum to determine the levels
f wild-type Vpr and mutant Vpr expression (Fig. 4C). In
ddition to the control plasmid, pZY-1, all cotransfected
ells expressed both HA-Vpr and mVpr. When HA-Vpr
nd wild-type Vpr were coexpressed, the protein levels
orresponded to the input levels of plasmid. For exam-
le, when an equal amount of plasmid was used (1:1),
he protein ratio was 0.99. When four times as much
A-Vpr expression plasmid (4:1) was used compared to
he Vpr expression plasmid, 3.5-fold more HA-Vpr was
xpressed and vice versa for a 1:4 ratio of HA-Vpr and
pr. However, other than Vpr79A, the Vpr mutant plas-
ids were expressed at lower levels than the wild-type
pr plasmid. Although as much as four times the input
utant plasmid was transfected, the mutant Vpr protein
evels were still lower than that of wild-type Vpr. Some of
he mutants expressed only 7–50% as much protein as
A-Vpr (Fig. 4C).
To determine the effect of mutant Vpr expression level
n HA-Vpr G2 cell cycle arrest, the cell cycle profile of
esistant cells was also analyzed (Fig. 4C, bottom). When
oth coexpressed proteins were competent for G2 cell
ycle arrest, i.e., Vpr 79S and 78Q, the level of G2 cell
ycle arrest was increased compared to that of HA-Vpr
lone. However, all the G2 cell cycle arrest null mutants,
pr79A, Vpr3S(2), Vpr79D, Vpr79Q, Vpr80A, and Vpr80K,
locked the wild-type Vpr G2 cell cycle arrest activities to
arious degrees (Figs. 4A and 4C). Complete blockade of
2 arrest activity was observed in the cells expressing
pr79D, Vpr79F, Vpr79Q, and Vpr80K when mutant Vpr
rotein levels were only 10–37% of that of HA-Vpr (Fig.
C).
utant Vpr does not block HIV-1 Vpr serine 79
hosphorylation
Since only 10 to 37% of the level of mutant Vpr could
ompletely block wild-type Vpr G2 cell cycle activity, we
ested whether this effect was due to an alteration of 79S
hosphorylation. 293VE-632 cells were cotransfected
ith pZH-HA-Vpr and pZY-1, pZY-125, pZY-79S, pZY-79D,
r pZY-80A at a ratio of 1:5 and then selected with Zeocin,
418, and hygromycin. The resistant cells were analyzed
or G2 cell cycle arrest and as before all the mutants
ould completely block HA-Vpr G2 cell cycle arrest ac-
ivity (data not shown). The resistant cells were then
ransfected with HIV-1 proviral clone p125Vpr(2) and
abeled with Tran[35S]label, to determine the total amount
of Vpr, or with [32P]orthophosphate to assess Vpr phos-
horylation in virions (Fig. 5). In the negative control, the
d
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TFIG. 4. Transdominant effect of G2 cell cycle arrest null HIV-1 Vpr mutants. (A) Schematic diagram of different Vpr mutants at positions 78, 79, and 80.
(1) indicates that the Vpr is phosphorylated and (2) Vpr is not phosphorylated (Zhou and Ratner, 2000). The average ratios of G1/(G2/M) are also listed. The
ata are the averages of two individual experiments for each mutant, reprinted with permission from Zhou and Ratner. (B) 293VE-632 cells were
otransfected with two plasmids at a 1:1 ratio and selected with the appropriate antibiotics. The cell cycle effects were analyzed in the presence of the
nducer. The FACScan analysis profiles shown are each one of two independent experiments, while the G1/(G2/M) data are from the average of the two
xperiments. (C) The effect of protein expression levels on the mutant Vpr transdominant activities. The cotransfected cells were split and either labeled with
ran[35S]label or fixed for cell cycle analysis. 35S-labeled HA-Vpr and mVpr were detected as described under Materials and Methods and are indicated with
arrows. The protein expression levels were determined by a phosphoimager. Using the G1/(G2/M) ratio of pZH-1-transfected cells as 0% and those of the
pZH-HA-Vpr/pZY-1-transfected cells (1:1, 4:1, or 1:4) as 100% each, the G2 cell cycle arrest percentage was calculated by comparison of the G1/(G2/M) from mVpr
to that from pZH-HA-Vpr/pZY-1 at the same plasmid ratio. The protein expression data and G2 arrest % are from the average of two independent experiments.
d138 ZHOU AND RATNERpZY-1/pZH-1 transfection, no Vpr signal could be de-
tected, while in the pZH-HA-Vpr/pZY-1 transfection, only
pZH-HA-Vpr could be detected (Fig. 5, lanes 1 and 2). In
Fig. 5, lanes 3–6, both HA-Vpr and wild-type Vpr or mVpr
could be clearly detected with similar levels of expres-
sion. HA-Vpr was phosphorylated in all cases. In lanes 3
and 4, wild-type Vpr and Vpr79S were also phosphory-
lated. Comparison of the ratio of 32P and 35S signals from
all dual expressions indicated that the transdominant
mutant Vpr had no significant effect on HA-Vpr phosphor-
ylation (Fig. 5).
DISCUSSION
In this study two methods were described for stable
ecdysone-regulated expression of HIV-1 Vpr in human
embryonic cells. One is an EBNA-based episomal vector
and the other is a stable cell line with the HIV-1 vpr gene
integrated into chromosomal DNA. The episomal vectors
facilitate the expression of different genes or mutants in
the same background. The advantage of these Vpr stable
cell lines is that the gene copy number is fixed and thus
Vpr is expressed homogeneously in the culture. Suc-
cessful coexpression of Vpr and Vpr mutants in 293VE
FIG. 5. The effect of Vpr transdominant mutants on wild-type Vpr
phosphorylation. HA-Vpr was coexpressed with wild-type Vpr, Vpr79S,
Vpr79D, and Vpr80A. Both 32P- and 35S-labeled Vpr were detected as
escribed under Materials and Methods and are indicated with arrows.
FIG. 6. Schematic representation of pZY-1 and pZH-1. The lines ind
EBNA1, EBV oriP, ecdysone-response element (E/GRE), minimal heat-
selectable markers Neo (neomycin) or Hyg (hygromycin) are also shown. pAcells further expands the use of this system to study Vpr
interaction with other cellular factors. Because the stable
cell lines also express EBNA1, which can support oriP
replication, an rpDR2 cDNA expression library can be
maintained in these cell lines to identify cellular factors
that can inhibit Vpr G2 cell cycle arrest activity. Therefore,
these two inducible expression methods provide valu-
able tools for the study of HIV-1 vpr gene functions.
It has been suggested that low levels of EBNA1 ex-
pression from rpDR2 are not sufficient for long-term
maintenance of the plasmid in primate cells. Therefore,
we cotransfected pCMV-EBNA1 and pVgRXR plasmids
into HEK293 cells to increase EBNA1 expression for
long-term persistence of transfected episomal plasmids.
However, a similar episomal vector for the Tet-inducible
system can be maintained in HeLa cells using the
EBNA1 expressed from the vector without additional
EBNA1 gene expression (Jost et al., 1997). This implies
that EBNA1 expressed from both pZY-1 and pZH-1 plas-
mids may support replication in the cells without addi-
tional EBNA1 (Fig. 6). Therefore, it is likely that the pZY-1
and pZH-1 plasmids can permit regulated gene expres-
sion and plasmid replication in other human pVgRXR cell
lines (e.g., commercial cell lines from Invitrogen and
Stratagene).
If transfected cells were maintained in the selection
medium, the expression of Vpr and its G2 cell cycle
arrest activity remained regulated by the inducer for at
least 2 months. In addition, the level of HIV-1 Vpr expres-
sion can be regulated by the amount of inducer in the
medium (data not shown). We have used this system to
successfully analyze different Vpr mutants that could not
be obtained without screening multiple stable cell lines
(Zhou and Ratner, 2000). In addition, this analytical sys-
tem is rapid, requiring only 1 week to obtain episomal
stable cells, compared to 6 weeks required using pIND
plasmids. More importantly, stable episomal cells avoid
the differences inherent in stable chromosome-recombi-
e portions of the plasmids derived from pIND or rpDR2 plasmid. The
romoter (PDHSP), human simplex virus TK promoter (PHSV TK), andicate th
shock pmeans the poly(A) signal.
139A NOVEL INDUCIBLE SYSTEM FOR HIV-1 Vprnant cell lines. Compared to retroviral expression sys-
tems, the episomal system has almost no size limitation,
can support plasmids up to 100 kb, and does not require
packaging of infectious particles (Wade-Martins et al.,
1999). However, we note that this system is restricted to
primate cells, since EBNA1 does not support EBV oriP in
cells of other species.
It is unclear why HEK293 cells have high background
expression with the Tet-inducible system (Howe et al.,
1995, and our observation). Our failure in generating
Tet-inducible Vpr-expressing HEK293 cells further indi-
cates the importance of the background expression level
of toxic genes. In this study, the ecdysone system had a
very low level of background gene expression. Thus, this
inducible system should be suitable for expression of
other toxic genes. Although the background of luciferase
activity was low in the nine cell lines presented in this
study, some of them did not express Vpr well after 7 to 10
days of G418 selection. One possible explanation is that
leaky expression of Vpr results in loss of pZY-Vpr in these
cells.
We have tried to control the gene expression level
using different amounts of plasmid. The mutant Vpr pro-
teins were not expressed as well as wild-type Vpr (Fig. 4),
with the exception of the 79A mutant. Like wild-type Vpr,
the 79A mutant has Ser94 and Ser96 residues. In all the
other mutants, the 94/96 serines were mutated to G and
P, respectively, to facilitate analysis of the Ser79 phos-
phorylation (Fig. 4A) (Zhou and Ratner, 2000). Thus,
Ser94 or Ser96 may be important for Vpr expression or
stability. In our previous publication, we have shown that
the Vpr79S and Vpr3S(2) mutants, which have mutations
at Ser94 and Ser96, are slightly less stable than wild-type
Vpr (Zhou and Ratner, 2000). It is unlikely that differences
in the codon usage for G or P residue at position 94 or 96
contribute to alterations in translational efficiency (Aus-
ubel et al., 1989).
It is interesting that all Vpr G2 cell cycle arrest null
mutants are transdominant to wild-type Vpr in G2 cell
cycle arrest. Since the substitution of S79 with A or D and
that of R80 with K are conservative substitutions, this
suggests that 79S and 80R are highly conserved for HIV
Vpr function. Furthermore, S79 and R80 are conserved in
all HIV-1 isolates (Zhou and Ratner, 2000). It is predicted
that Vpr forms a dimer through interactions involving a
leucine-zipper motif (residues 53 to 81) (Wecker and
Roques, 1999). From the helix–helix wheel structure, res-
idue H78 would be involved in dimerization, while S79
and R80 would face outward and are likely to be involved
in interactions with other proteins. It is interesting that
the location of R73 on the helix–helix wheel is precisely
one turn from R80, and R73 mutants are also transdomi-
nant to wild-type Vpr in G2 cell cycle arrest (Sawaya et
al., 2000). However, no protein expression data were
shown in that previous study (Sawaya et al., 2000).
Therefore R73, S79, and R80 may be directly involved inthe interaction of Vpr with a cellular target protein. Our
results show that as little as 10 to 37% of mutant Vpr
versus wild-type Vpr levels can completely block wild-
type Vpr activity. Therefore, these sites may be good
targets for anti-Vpr reagent development. In addition, Vpr
has been used as a vector for delivering therapeutic
reagents into HIV-1 virions, and therefore this may im-
prove the development of anti-Vpr reagents (Wu et al.,
1995). The G2 cell cycle arrest function of Vpr has been
suggested to be important for optimal levels of the virus
production. Furthermore, virion-associated Vpr is suffi-
cient to cause G2 cell cycle arrest without de novo
protein synthesis. Since mutations of residue 79 do not
affect Vpr packaging into virions, transdominant mutants
may be better than wild-type Vpr as vectors for therapeu-
tic purposes.
The molecular basis of the transdominant effect is
unclear. It is reasonable to assume that the homodimer
of mutant Vpr and the heterodimer of mutant Vpr and
wild-type Vpr are inactive. It is also possible that the
heterodimer or mutant homodimer has greater affinity for
a Vpr target(s) than wild-type Vpr homodimer. We have
shown that transdominant mutants do not affect Vpr
phosphorylation. Therefore, it is more likely that mutant
Vpr affects a downstream Vpr target(s). Ongoing studies
are examining the association of Vpr and these trans-
dominant mutants to known Vpr-interactive cellular pro-
teins (Gragerov et al., 1998; Mahalingam et al., 1998;
Withers-Ward et al., 1997) to further decipher the mech-
anism of HIV-1 Vpr G2 cell cycle arrest.
MATERIALS AND METHODS
Construction of plasmid
The plasmids pVgRXR, pIND, and pIND-LacZ were
purchased from Invitrogen (San Diego, CA). rpDR2 and
pCMV-EBNA1 were purchased from Clontech (Palo Alto,
CA). pZY-1 was constructed by ligation of the NruI frag-
ment of rpDR2 containing oriP and the EBNA1 coding
region to the HincII fragment of pIND containing E/GRE
and a neomycin-resistance expression cassette (Fig. 6).
pZH-1 was generated by digestion of rpDR2 with EcoRV/
XbaI and ligation into EcoRV/XbaI-digested pZY-1 to re-
place the neo resistance gene cassette with the hygro-
mycin gene (Fig. 6). To generate pIND-Luc, the luciferase
gene from pUHD-13 (kindly provided by Dr. H. Bujard;
Gossen and Bujard, 1992) was digested with BamHI/XbaI
and cloned into pIND. To obtain pZY-Luc, the BglII/XbaI
fragment containing the luciferase gene and E/GRE from
pIND-Luc was cloned into the BglII/XbaI sites in pZY-1. To
express Vpr in the ecdysone-inducible expression sys-
tem, pTM-VPR was digested with NcoI and treated with
Klenow DNA polymerase I followed by BamHI digestion.
The Vpr fragment was then cloned into pIND at the
HindIII/BamHI sites after blunting the HindIII site with
Klenow DNA polymerase I. To clone Vpr into pZY-1, pIND-
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140 ZHOU AND RATNERVpr was digested with BglII/XhoI and cloned into pZY-1
BglII/XhoI sites to get pZY-VPR (Zhou and Ratner, 2000).
Vpr mutants Vpr3S(2), Vpr79A, Vpr79S, Vpr79D, Vpr79Q,
pr80A, and Vpr80K, as described previously, were di-
ested with SalI/EcoNI and cloned into pZY-Vpr SalI/
amHI sites after the BamHI site was partially filled in
ith Klenow DNA polymerase I exo2 in the presence of
GTP, dATP, and TTP (Zhou and Ratner, 2000). The SalI
ite is at codons 76–77 of Vpr. Wild-type Vpr and Vpr
utants were cloned into pZH-1 in a similar fashion. To
lone HA-Vpr into plasmid pZY-1 or pZH-1, pcDNA-tag-Vpr
kindly provided by Dr. N. R. Landau; Di Marzio et al.,
995) was digested with HindIII and blunted with Klenow
NA polymerase I followed by XhoI digestion. The puri-
ied HA-Vpr fragment was then cloned into NheI/XhoI
ites on the pZY-1 or pZH-1 vector after blunt ending the
heI fragment with Klenow DNA polymerase I.
ell lines, DNA transfection, and luciferase assays
HEK293 cells were maintained in Dulbecco’s modified
agle’s medium (DMEM) supplemented with 10% heat-
nactivated fetal calf serum (FCS) and 100 U of penicillin/
treptomycin per milliliter. The 293VE cell lines were
btained by cotransfecting plasmids, pVgRXR and pCMV-
BNA1, using Lipofectamine into HEK293 cells (Zhou and
atner, 2000). The transfected cells were split into 96-
ell plates (50 or 100 cells/well) and cultured for 2 days
ollowed by 400 mg/ml Zeocin (Invitrogen) selection for
2 days. The individual colonies were amplified and
ested for gene expression according to the protocol
rovided by the manufacturer (Invitrogen). Briefly, the
ndividual cell lines were expanded and plated into 24-
ell plates (about 104 cells/well) and transfected with
ZY-Luc overnight. Then the cells were split into 2 wells
nd cultured for an additional 24 h. The luciferase activ-
ties were analyzed at 24 h in the presence or absence of
he inducer, 1 mM muristerone A (Invitrogen). To test the
EBNA1 expression in these cell lines, the cells were
transfected with pZY-1 or pIND overnight and then se-
lected with 750 mg/ml G418 sulfate (GIBCO BRL, Gaith-
ersburg, MD) for 5 to 7 days. The surviving cells were
examined. If the cells expressed EBNA1, cell survival
equaled the transfection efficiency (;50%) and ex-
ceeded that of cells transfected with pIND. The cell lines
were maintained in DMEM supplemented with 10% FCS,
100 U of penicillin/streptomycin per milliliter, and 100
mg/ml Zeocin. To coexpress two proteins, pZY and pZH
plasmids were cotransfected into 293VE cells and se-
lected with the medium containing 750 mg/ml G418 sul-
fate, 200 mg/ml hygromycin, and 100 mg/ml Zeocin.
For luciferase assays, the cells were harvested by
irect lysis in tissue culture dishes in 13 lysis buffer
Promega, Madison, WI) for 20 min at 4°C. Luciferase
ctivity was determined using a Luminometer Monolight
010, Series 1036 (Analytical Luminescence Labs, Ham-en, CT). Protein concentration of each cell lysate was
etermined using the microassay method (Bio-Rad, Her-
ules, CA, or Pierce, Rockford, IL) following the protocols
rovided.
mmunoprecipitation
To examine Vpr gene expression, 1 3 106 resistant
ells from 293VE cells transfected with Vpr or Vpr mutant
xpression plasmids were plated into six-well plates and
abeled with 100 mCi/ml Tran[35S]label (ICN, Costa Mesa,
A) for 16–20 h in the absence/presence of 1 mM muris-
terone A. The cell lysates were used to detect Vpr ex-
pression by radioimmunoprecipitation with Vpr anti-
serum and SDS–PAGE as described elsewhere (Zhou
and Ratner, 2000).
Phosphorylation analysis
To examine phosphorylation of S79 in the Vpr mutants,
293VE cells were transfected with different Vpr mutant
expression plasmids and selected with 750 mg/ml G418
sulfate for 5 days. G418-resistant cells (5 3 105) were
plated into six-well plates, induced for Vpr expression for
24 h with 1 mM muristerone A, and then transfected with
p125-Vpr(2) proviral DNA. The transfected cells were
split and continued in culture for 24 h in the presence of
the inducer. Then cells were labeled with [32P]orthophos-
phate or Tran[35S]label overnight in the presence of the
nducer. The supernatant containing HIV-1 virions was
arvested to test Vpr expression and phosphorylation by
mmunoprecipitation as described earlier.
low cytometry
Resistant 293VE cells (2.5 3 105) with Vpr or Vpr
mutant expression plasmids were plated into 12-well
plates and cultured in the appropriate selection medium
with or without inducer for 36 to 48 h. The cells were
harvested and prepared for flow cytometry as described
elsewhere (Zhou and Ratner, 2000). Briefly, the resistant
cells (about 3.0 3 105) were pelleted and resuspended
nto 0.1 ml of PBS with 1% glucose, fixed by the addition
f 1 ml of 70% ethanol, and stored at 4°C for at least 15 h.
he fixed cells were pelleted and resuspended in 0.5 ml
f staining solution (1% glucose, 50 U/ml RNase A, and
0 mg/ml propidium iodide in PBS) for at least 60 min
efore flow cytometric analysis with the Cellquest pro-
ram (Becton–Dickinson Immunocytometry Systems,
an Diego, CA).
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